Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU
May 25, 2021 09:00 ET
|
Auris Medical AG
Meeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical...
Auris Medical Provides Update on Bentrio Program in Allergy
May 07, 2021 09:05 ET
|
Auris Medical AG
BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians...
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
April 13, 2021 07:45 ET
|
Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...
Auris Medical to Provide Business Update on AM-301 Program on Tuesday, April 13, 2021
April 08, 2021 08:00 ET
|
Auris Medical AG
Hamilton, Bermuda, April 8, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis
January 29, 2021 08:30 ET
|
Auris Medical AG
Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Provides Business Update
December 15, 2020 08:30 ET
|
Auris Medical AG
Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises AM-301 program progressing towards clinical and regulatory milestones Strategy review ongoing Hamilton,...
Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection
December 01, 2020 09:00 ET
|
Auris Medical AG
Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001)Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection Hamilton, Bermuda, December...
Auris Medical Launches Development of Drug-Free Nasal Spray for Protection against Airborne Pathogens and Allergens
September 08, 2020 08:30 ET
|
Auris Medical AG
Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99%Creation of dedicated...